Company Filing History:
Years Active: 2013
Title: The Innovative Contributions of Charles Thürlemann
Introduction
Charles Thürlemann is a notable inventor based in Egnach, Switzerland. He has made significant contributions to the field of biomedical engineering, particularly in the development of systems for analyzing bodily fluids. His work is characterized by a focus on improving diagnostic methods and enhancing the understanding of coagulation anomalies.
Latest Patents
Thürlemann holds a patent for a "System for differential determination of a proteolytic enzyme level in a bodily fluid." This innovative system includes an assortment of sensors, where the working electrode of each sensor is covered with a specific reagent of a given proteolytic enzyme. The system is designed to measure the release of leaving groups (LG) via the action of the enzyme. It features a measuring apparatus with an electronic circuit that imposes a current, allowing for the detection of signals representative of the release of LG over time. This technology can be utilized to determine factors responsible for coagulation anomalies in plasma or whole blood samples.
Career Highlights
Thürlemann is associated with Asulab S.A., a company that focuses on advanced technological solutions in the biomedical field. His work at Asulab has allowed him to apply his innovative ideas in practical settings, contributing to the advancement of medical diagnostics.
Collaborations
Throughout his career, Thürlemann has collaborated with talented professionals, including André Haeberli and Erik Jan Frenkel. These collaborations have fostered a creative environment that encourages the exchange of ideas and the development of cutting-edge technologies.
Conclusion
Charles Thürlemann's contributions to the field of biomedical engineering exemplify the impact of innovation on medical diagnostics. His patented system for enzyme level determination showcases his commitment to improving healthcare solutions. Through his work and collaborations, he continues to influence the future of medical technology.